New combo therapy aims to fight hard-to-treat lymphoma
NCT ID NCT05996185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding the drug mogamulizumab to standard chemotherapy for people with aggressive T-cell lymphoma, a type of blood cancer. About 22 adults with newly diagnosed or returning lymphoma will receive the combination treatment. The goal is to see if more patients achieve complete remission and to monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Yale Cancer Center, Clinical Trials Office
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
- New study aims to decode PTCL by genetic subtype
- Massive T-Cell lymphoma database aims to unlock new insights
- New CAR-T therapy targets tough T-Cell cancers in early trial
- Skin cancer study digs into patient data to spot trends